Antibiotic enters final tests for deadly superbug behind hospital infection
A deadly antibiotic, zosurabalpin, has entered the final human tests to fight a deadly superbug. Currently, no new antibiotics targeting this superbug have been developed in five decades.
In short
- A new experimental medicine & nbsp; Acinetobacter baumannii targets infection
- Antibiotics have entered phase 3 human tests
- No new antibiotics have emerged in more than 50 years for this superbug
A new drug that can help deal with one of the world’s most dangerous drug-resistant bacteria, now entering its final stage of human tests. This potential success can help in the global fight against antibiotic resistance.
Swiss pharmaceutical giant Roshe announced on Monday that its experimental antibiotic, Zosurabalpin, Phase 3, developed in collaboration with Harvard University, is moving forward in tests.
This final stage will test the drug on about 400 patients worldwide, which will focus on its ability to treat infections caused by the Acinetobacter Baumannii, a bacteria that causes severe hospital-disconnected infections such as pneumonia and sepsis.
Acinetobacter Baumannii is a small, rod-shaped, gram-negative bacteria. Scientists call it a “opportunistic bacterial pathogen” because it affects people with a weak immune system, excessive in hospital settings.
Acinetobacter Baumannii is recognized as “immediate threat” by the US Center for Disease Control and Prevention (CDC), and has become increasingly resistant to existing antibiotics.
Currently, no new antibiotics targeting this superbug have been developed in five decades.
The set of Zosurbalpin is that it works in a new way, using a mechanism that the bacteria have not yet found any way to protest. This fresh approach brings new optimism to an area where many treatments are failing due to antibiotic resistance.
Infections caused by drug resistant bacteria are not only difficult to treat, but also broad. Globally, Sepsis is estimated to have 11 million deaths a year, while community-deficit pneumonia (CAP) kills 3 to 4 million people annually, especially among the elderly.
“Antimicrobial resistance is one of the biggest infectious disease challenges for public health. Our goal is to contribute new innovations to overcome this growing danger.”
Larry Tsai, head of immunology and product development at Roshe’s US Unit Gennentake, said that every country has an Acinetobacter Bomanei. He said that unique biology involved in developing Zosubalpin can also give rise to future discoveries in the fight against other resistant bacteria.
Step 3 will test the effects of zosurabalpin to current standard remedies, and if successful, the drug may be prepared for approval by the end of this decade.
